Microcytic Anemia in CKD: Is Ferritin 120 Enough to Exclude Iron Deficiency?
63-year-old woman with stage 3b CKD (eGFR 38 mL/min/1.73 m²), type 2 diabetes, and fatigue has Hb 9.1 g/dL, MCV 76 fL, RDW 17.8%, ferritin 120 ng/mL, TSAT 14%, CRP 28 mg/L, and absolute reticulocyte count 21 × 10^9/L. She has no overt blood loss, takes no iron, and has not received ESA therapy. The anemia is microcytic with a low reticulocyte response, but the ferritin is above the usual 30 ng/mL cutoff used in otherwise healthy adults. The clinician asks whether iron deficiency is present and whether IV iron is justified before escalating to an ESA.
1. How should the ferritin and TSAT be interpreted in this setting, and why can ferritin be misleading?
Read the worked answer
Ferritin is an acute-phase reactant, so 120 ng/mL is not a normal result in a patient with CRP 28 mg/L. In inflammation and CKD, hepcidin rises, iron is sequestered in macrophages, and ferritin can be normal or high while iron delivery to erythroid precursors is inadequate. The TSAT of 14% is low and indicates insufficient circulating iron for marrow use. The microcytosis, high RDW, and low reticulocyte response also fit iron-restricted erythropoiesis. In CKD, iron deficiency is often considered when TSAT is ≤20% and ferritin is ≤100 ng/mL, but values of 100–300 ng/mL are a gray zone, especially with inflammation. Therefore, ferritin 120 does not exclude iron deficiency; the combination of low TSAT, high CRP, microcytosis, and low reticulocytes makes iron deficiency or mixed iron deficiency/anemia of inflammation likely enough to evaluate further before assuming ESA resistance.
2. Which additional laboratory test would most help distinguish iron deficiency from anemia of inflammation, and what are its limitations?
Read the worked answer
Reticulocyte hemoglobin content (CHr) or soluble transferrin receptor (sTfR) is more informative than ferritin alone. CHr reflects iron available to erythroid precursors over the preceding few days; a low CHr supports iron deficiency, whereas a normal CHr argues against it. sTfR is less affected by inflammation than ferritin because it reflects erythroid receptor mass and increases in iron deficiency, but it can be influenced by erythroid hyperplasia, hemolysis, or recent ESA use. The sTfR/log ferritin ratio can help when inflammation is present. No test is perfect: bone marrow iron remains the reference method but is impractical. In this patient, a low CHr or elevated sTfR would support a trial of iron, while a normal CHr with high CRP would favor anemia of inflammation and prompt a search for another cause.
3. If IV iron is given, what should be monitored to judge response, and why might ferritin rise without a hemoglobin response?
Read the worked answer
Monitor hemoglobin and reticulocyte count at about 2–4 weeks, along with TSAT and ferritin. A reticulocyte rise followed by a hemoglobin increase indicates iron was limiting erythropoiesis. Ferritin can rise after IV iron simply because iron stores were replaced, and it can also remain elevated because of ongoing inflammation; therefore, a rising ferritin is not proof of a hematologic response. If hemoglobin does not rise despite adequate iron, reassess for ongoing blood loss, inflammation, B12/folate deficiency, hemolysis, or ESA resistance. Do not use ferritin alone to decide whether to continue iron or start an ESA.